Document ID: FDA-2015-N-3838-0001
Agency: fda
Document Type: Rule
Title: Medical Devices; General Hospital and Personal Use Devices; Classification of the Ultraviolet Radiation Chamber Disinfection Device
Posted Date: 2015-11-20T05:00Z

[Federal Register Volume 80, Number 224 (Friday, November 20, 2015)]
[Rules and Regulations]
[Pages 72587-72589]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29660]

[[Page 72587]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 880

[Docket No. FDA-2015-N-3838]

Medical Devices; General Hospital and Personal Use Devices; 
Classification of the Ultraviolet Radiation Chamber Disinfection Device

AGENCY: Food and Drug Administration, HHS.

ACTION: Final order.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is 
classifying the ultraviolet (UV) radiation chamber disinfection device 
into class II (special controls). The special controls that will apply 
to the device are identified in this order and will be part of the 
codified language for the UV radiation chamber disinfection device 
classification. The Agency is classifying the device into class II 
(special controls) in order to provide a reasonable assurance of safety 
and effectiveness of the device.

DATES: This order is effective November 20, 2015. The classification 
was applicable on December 20, 2011.

FOR FURTHER INFORMATION CONTACT: Elizabeth Claverie, Center for Devices 
and Radiological Health, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 66, Rm. 2508, Silver Spring, MD 20993-0002, 301-
796-6298.

SUPPLEMENTARY INFORMATION:

I. Background

    In accordance with section 513(f)(1) of the Federal Food, Drug, and 
Cosmetic Act (the FD&C Act) (21 U.S.C. 360c(f)(1)), devices that were 
not in commercial distribution before May 28, 1976 (the date of 
enactment of the Medical Device Amendments of 1976), generally referred 
to as postamendments devices, are classified automatically by statute 
into class III without any FDA rulemaking process. These devices remain 
in class III and require premarket approval, unless and until the 
device is classified or reclassified into class I or II, or FDA issues 
an order finding the device to be substantially equivalent, in 
accordance with section 513(i) of the FD& C Act, to a predicate device 
that does not require premarket approval. The Agency determines whether 
new devices are substantially equivalent to predicate devices by means 
of premarket notification procedures in section 510(k) of the FD&C Act 
(21 U.S.C. 360(k)) and part 807 (21 CFR part 807) of the regulations.
    Section 513(f)(2) of the FD&C Act, as amended by section 607 of the 
Food and Drug Administration Safety and Innovation Act (Pub. L. 112-
144), provides two procedures by which a person may request FDA to 
classify a device under the criteria set forth in section 513(a)(1) of 
the FD&C Act. Under the first procedure, the person submits a premarket 
notification under section 510(k) of the FD&C Act for a device that has 
not previously been classified and, within 30 days of receiving an 
order classifying the device into class III under section 513(f)(1) of 
the FD&C Act, the person requests a classification under section 
513(f)(2) . Under the second procedure, rather than first submitting a 
premarket notification under section 510(k) of the FD&C Act and then a 
request for classification under the first procedure, the person 
determines that there is no legally marketed device upon which to base 
a determination of substantial equivalence and requests a 
classification under section 513(f)(2) of the FD&C Act. If the person 
submits a request to classify the device under this second procedure, 
FDA may decline to undertake the classification request if FDA 
identifies a legally marketed device that could provide a reasonable 
basis for review of substantial equivalence with the device or if FDA 
determines that the device submitted is not of ``low-moderate risk'' or 
that general controls would be inadequate to control the risks and 
special controls to mitigate the risks cannot be developed.
    In response to a request to classify a device under either 
procedure provided by section 513(f)(2) of the FD&C Act, FDA will 
classify the device by written order within 120 days. This 
classification will be the initial classification of the device. In 
accordance with section 513(f)(1) of the FD&C Act, FDA issued an order 
on October 28, 2010, classifying the Vioguard Self-Sanitizing Keyboard 
into class III, because it was not substantially equivalent to a device 
that was introduced or delivered for introduction into interstate 
commerce for commercial distribution before May 28, 1976, or a device 
which was subsequently reclassified into class I or class II. On 
November 2, 2010, Vioguard submitted a request for classification of 
the Vioguard Self-Sanitizing Keyboard under section 513(f)(2) of the 
FD&C Act. The manufacturer recommended that the device be classified 
into class II (Ref. 1).
    In accordance with section 513(f)(2) of the FD&C Act, FDA reviewed 
the request in order to classify the device under the criteria for 
classification set forth in section 513(a)(1) of the FD&C Act. FDA 
classifies devices into class II if general controls by themselves are 
insufficient to provide reasonable assurance of safety and 
effectiveness, but there is sufficient information to establish special 
controls to provide reasonable assurance of the safety and 
effectiveness of the device for its intended use. After review of the 
information submitted in the request, FDA determined that the device 
can be classified into class II with the establishment of special 
controls. FDA believes these special controls will provide reasonable 
assurance of the safety and effectiveness of the device.
    Therefore, on December 20, 2011, FDA issued an order to the 
requestor classifying the device into class II. FDA is codifying the 
classification of the device by adding 21 CFR 880.6600.
    Following the effective date of this final classification order, 
any firm submitting a premarket notification (510(k)) for a UV 
radiation chamber disinfection device will need to comply with the 
special controls named in this final order. The device is assigned the 
generic name UV radiation chamber disinfection device, and it is 
identified as a UV chamber disinfection device intended for the low-
level surface disinfection of non-porous equipment surfaces by dose-
controlled UV irradiation. This classification does not include self-
contained open chamber UV disinfection devices intended for whole room 
disinfection in a health care environment.
    FDA has identified the following risks to health associated 
specifically with this type of device, as well as the mitigation 
measures required to mitigate these risks in table 1.

  Table 1--Ultraviolet Radiation Chamber Disinfection Device Risks and
                           Mitigation Measures
------------------------------------------------------------------------
            Identified risks                   Mitigation measures
------------------------------------------------------------------------
Inadequate Equipment Disinfection......  Performance Testing.
                                         Labeling.

[[Page 72588]]

 
UV Radiation Exposure..................  Performance Testing.
                                         Labeling.
Electrical Shock.......................  Electrical Safety Testing.
Electromagnetic Interference...........  Electromagnetic Compatibility
                                          (EMC) Testing.
                                         Labeling.
Ozone Exposure.........................  Ozone Generation Limits.
                                         Labeling.
Processed Equipment Incompatibility....  Performance Testing.
                                         Labeling.
Contamination of Device................  Cleaning and Disinfection
                                          Validation.
                                         Labeling.
Software Malfunction...................  Hazard Analysis of Software.
                                         Software Verification and
                                          Validation.
------------------------------------------------------------------------

    FDA believes that the special controls in Sec.  880.6600(b)(1) 
through (4), in addition to the general controls, address these risks 
to health and provide reasonable assurance of the safety and 
effectiveness.
    Section 510(m) of the FD&C Act provides that FDA may exempt a class 
II device from the premarket notification requirements under section 
510(k) of the FD&C Act, if FDA determines that premarket notification 
is not necessary to provide reasonable assurance of the safety and 
effectiveness of the device. For this type of device, FDA has 
determined that premarket notification is necessary to provide 
reasonable assurance of the safety and effectiveness of the device. 
Therefore, this device type is not exempt from premarket notification 
requirements. Persons who intend to market this type of device must 
submit to FDA a premarket notification, prior to marketing the device, 
which contains information about the UV radiation chamber disinfection 
device they intend to market.

II. Environmental Impact

    We have determined under 21 CFR 25.34(b) that this action is of a 
type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.

III. Paperwork Reduction Act of 1995

    This final order establishes special controls that refer to 
previously approved collections of information found in other FDA 
regulations. These collections of information are subject to review by 
the Office of Management and Budget (OMB) under the Paperwork Reduction 
Act of 1995 (44 U.S.C. 3501-3520). The collections of information in 
part 807, subpart E, regarding premarket notification submissions have 
been approved under OMB control number 0910-0120, and the collections 
of information in 21 CFR part 801, regarding labeling have been 
approved under OMB control number 0910-0485.

IV. Reference

    The following reference is on display in the Division of Dockets 
Management (see ADDRESSES) and is available for viewing by interested 
persons between 9 a.m. and 4 p.m., Monday through Friday; it is also 
available electronically at http://www.regulations.gov.

    1. DEN100013: de novo request per 513(f)(2) from Vioguard, dated 
November 2, 2010.

List of Subjects in 21 CFR Part 880

    Medical devices.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs, 21 CFR part 
880 is amended as follows:

PART 880--GENERAL HOSPITAL AND PERSONAL USE DEVICES

0
1. The authority citation for 21 CFR part 880 continues to read as 
follows:

    Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.

0
2. Section 880.6600 is added to subpart G to read as follows:

Sec.  880.6600  Ultraviolet (UV) radiation chamber disinfection device.

    (a) Identification. An ultraviolet (UV) radiation chamber 
disinfection device is intended for the low-level surface disinfection 
of non-porous equipment surfaces by dose-controlled UV irradiation. 
This classification does not include self-contained open chamber UV 
radiation disinfection devices intended for whole room disinfection in 
a health care environment.
    (b) Classification--Class II (special controls). The special 
controls for this device are:
    (1) Performance testing must demonstrate the following:
    (i) The chamber's ability to control the UV radiation dose during 
operation.
    (ii) The chamber's disinfection performance through microbial 
challenge testing.
    (iii) Evidence that the equipment intended to be processed is UV 
compatible.
    (iv) Validation of the cleaning and disinfection procedures.
    (v) The ability of the device to continue to perform to all 
specification after cleaning and disinfection.
    (vi) Whether the device generates ozone (if so, 21 CFR 801.415, 
Maximum acceptable level of ozone, applies).
    (2) Appropriate software verification, validation, and hazard 
analysis must be performed.
    (3) Appropriate analysis and/or testing must validate electrical 
safety, mechanical safety, and electromagnetic compatibility of the 
device in its intended use environment.
    (4) The labeling must include:
    (i) UV hazard warning labels.
    (ii) Explanation of all displays and/or labeling on user interface.
    (iii) Explanation of device safety interlocks.
    (iv) Explanation of all disinfection cycle signals, cautions and 
warnings.
    (v) Device operating procedures.
    (vi) Identification of the expected UV lamp operational life and 
instructions for procedures on replacement of the UV lamp when needed.
    (vii) Procedures to follow in case of UV lamp malfunction or 
failure.
    (viii) Procedures for disposing of mercury-containing UV lamps, if 
applicable.
    (ix) Identification of specific equipment that is compatible with 
the UV radiation dose generated by the device and that can safely 
undergo UV

[[Page 72589]]

radiation low-level disinfection in the chamber device.
    (x) Description of the required preparation of equipment for 
disinfection in the UV radiation chamber device.
    (xi) Identification of the specific microbes used in successful 
performance testing of the device.
    (xii) Validated instructions for cleaning and disinfection of the 
device.

    Dated: November 17, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-29660 Filed 11-19-15; 8:45 am]
BILLING CODE 4164-01-P